Advanced MalignanciesPhase 1NCT07426757
An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers
A Phase 1 study testing PF-07994525 and Midazolam in people with Advanced Malignancies and Advanced Cancer, run by Pfizer at 30 sites in 2 countries.
Trial summary
This is an open-label, dose escalation and dose expansion study evaluating the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and antitumor activity of PF-07994525 in participants with R/R MM. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Advanced Malignancies, Advanced Cancer
- What is being tested?
- PF-07994525 and Midazolam
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 120 participants
- Where
- 30 sitesin 2 countries
- Study dates
- 1 Jul 2026to 10 Jul 2030
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participants aged 18 years or older (or the minimum age of consent in accordance with local regulations) at the time of informed consent.
- Prior diagnosis of MM as defined according to IMWG criteria (Rajkumar et al. 2014)
- Measurable disease based on IMWG criteria as defined by at least 1 of the following:
- Serum M-protein >0.5 g/dL by serum protein electrophoresis (SPEP)
- Urinary M-protein excretion >200 mg/24 hours by urine protein electrophoresis (UPEP)
- Serum immunoglobulin Free Light Chain (FLC) ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio (<0.26 or >1.65)
- Participants must be refractory to, or intolerant to, all established therapies known to provide clinical benefit in multiple myeloma that are an appropriate therapeutic option, in the judgement of the investigator. A minimum of 3 prior lines of therapy are required.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
Who cannot join
- Active plasma cell leukemia, Smoldering MM, Waldenströms macroglobulinemia, Amyloidosis, POEMS Syndrome.
- Autologous stem cell transplant within 12 weeks prior to enrollment or active Graft-versus-host disease (GVHD).
- Active or suspected cerebral/meningeal disease related to the underlying malignancy.
- Any active, uncontrolled bacterial, fungal, or viral infection, including (but not limited to) COVID-19, Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), known HIV or AIDS related illness, unless deemed not clinically significant by the investigator (eg, onychomycosis).
Trial locations and contacts
30 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
30 sites in 2 countries
United States27 sites, 27 recruiting
- Recruiting
Emory University Hospital Midtown
Atlanta, Georgia, 30308
- Recruiting
Emory University Hospital
Atlanta, Georgia, 30322
- Recruiting
Winship Cancer Institute, Emory University
Atlanta, Georgia, 30322
- Recruiting
Ohio State University Hospitals
Columbus, Ohio, 43210
- Recruiting
The James Cancer Hospital and Solove Research Institute
Columbus, Ohio, 43210
- Recruiting
The James Outpatient Care West Campus
Columbus, Ohio, 43210
- Recruiting
Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center
Coral Gables, Florida, 33146
- Recruiting
Sylvester Comprehensive Cancer Center - Coral Springs
Coral Springs, Florida, 33065
- Recruiting
University of Miami Hospital and Clinics - Deerfield Beach
Deerfield Beach, Florida, 33442
- Recruiting
Colorado Blood Cancer Institute
Denver, Colorado, 80218
- Recruiting
Presbyterian/St. Luke's Medical Center
Denver, Colorado, 80218
- Recruiting
Sylvester Comprehensive Cancer Center- Doral
Doral, Florida, 33166
- Recruiting
Sylvester Comprehensive Cancer Center - Hollywood
Hollywood, Florida, 33021
- Recruiting
Sylvester Comprehensive Cancer Center
Miami, Florida, 33136
- Recruiting
University of Miami Hospital and Clinics
Miami, Florida, 33136
- Recruiting
Sylvester Comprehensive Cancer Center- Kendall
Miami, Florida, 33176
- Recruiting
Sarah Cannon Research Institute - Pharmacy
Nashville, Tennessee, 37203
- Recruiting
SCRI Oncology Partners
Nashville, Tennessee, 37203
- Recruiting
Tristar BMT
Nashville, Tennessee, 37203
- Recruiting
TriStar Centennial Medical center
Nashville, Tennessee, 37203
- Recruiting
Smilow Cancer Hospital - Yale New Haven Health
New Haven, Connecticut, 06510
- Recruiting
Yale-New Haven Hospital-Yale Cancer Center
New Haven, Connecticut, 06510
- Recruiting
Smilow Cancer Hospital Phase 1 Unit
New Haven, Connecticut, 06511
- Recruiting
Yale University - Smilow Cancer Hospital; C/O Thomas Ferencz, RPh, BCOP
New Haven, Connecticut, 06511
- Recruiting
Smilow Cancer Hospital - North Haven
North Haven, Connecticut, 06473
- Recruiting
Sylvester Comprehensive Cancer Center - Sole Mia
North Miami, Florida, 33181
- Recruiting
Sylvester Comprehensive Cancer Center - Plantation
Plantation, Florida, 33324
Canada3 sites, 3 recruiting
- Recruiting
Arthur J.E. Child Comprehensive Cancer Centre
Calgary, Alberta, T2N 5G2
- Not yet recruiting
Juravinski Cancer Centre
Hamilton, Ontario, L8V 5C2
- Recruiting
University Health Network- Princess Margaret Cancer Centre
Toronto, Ontario, M5G2M9
About this study
Official title: AN OPEN-LABEL PHASE 1 STUDY TO EVALUATE PF-07994525 IN PARTICIPANTS WITH ADVANCED MALIGNANCIES
This is an open-label, dose escalation and dose expansion study evaluating the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and antitumor activity of PF-07994525 in participants with R/R MM.
The study will consist of 2 parts: Part 1 (Dose Escalation) will consist of PF-07994525 dose escalation to assess the safety, tolerability, and preliminary antitumor activity in participants with R/R MM. In Part 2 (Dose expansion), PF-07994525 may be evaluated in additional participants with R/R MM to further assess safety, PK, PD, and preliminary anti-tumor activity.
- Conditions
- Advanced Malignancies, Advanced Cancer
- Being tested
- PF-07994525, Midazolam
- Keywords
- Advanced Malignancies, Advanced Cancers, Advanced Cancer
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PF-07994525Drug
Oral administration
MidazolamDrug
Oral administration
| Study group | Role | What they receive |
|---|---|---|
| Part 1 | Experimental | Monotherapy Dose Expansion Receives: Drug: PF-07994525; Drug: Midazolam |
| Part 2 | Experimental | Monotherapy Dose Escalation Receives: Drug: PF-07994525 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Type, incidence and severity of participants with adverse events (AEs)
Type, incidence, severity (graded by National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] version 5.0), timing, seriousness, and relatedness of adverse events (AEs)
Measured: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Type, incidence and severity of participants with laboratory abnormalities
Type, incidence, and severity (graded by NCI CTCAE version 5.0) of laboratory abnormalities
Measured: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Number of participants with dose modifications
Frequency of dose modifications (eg, dose delay, treatment interruptions, dose reductions, and treatment discontinuations) due to AEs
Measured: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)
Occurrence of DLTs as defined by the protocol
Measured: Baseline to end of DLT evaluation period
Part 1: Recommended Monotherapy Dose for Expansion (RDE)
RDE will be based on cumulative safety, preliminary antitumor activity and pharmacokinetics findings
Measured: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Part 2: Recommended Dose for future development
Safety, and preliminary anti-tumor activity
Measured: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Secondary outcomes (20)
Objective response rate (ORR) per International Myeloma Working Group (IMWG) response criteria as determined by investigator.
Measured: Baseline until the date of the first documentation of disease progression, death, or start of new anticancer therapy (approximately 2 years)
Complete response rate (CRR) per International Myeloma Working Group (IMWG) response criteria as determined by investigator.
Measured: Baseline until the date of the first documentation of disease progression, death, or start of new anticancer therapy (approximately 2 years)
Time to response (TTR) per IMWG as determined by investigator
Measured: Baseline until the date of the first documentation of disease progression, death, or start of new anticancer therapy (approximately 2 years)
Duration of response (DOR) per IMWG as determined by investigator
Measured: Baseline until the date of the first documentation of disease progression, death, or start of new anticancer therapy (approximately 2 years)
Duration of complete response (DOCR) per IMWG as determined by investigator
Measured: Baseline until the date of the first documentation of disease progression, death, or start of new anticancer therapy (approximately 2 years)
Progression-free survival (PFS) per IMWG as determined by investigator
Measured: Baseline until the date of the first documentation of disease progression, death, or start of new anticancer therapy (approximately 2 years)
Overall survival (OS)
Measured: Baseline until the date of the first documentation of disease progression, death, or start of new anticancer therapy (approximately 2 years)
Single, Multiple Dose and food effect: Maximum Observed Concentration (Cmax)
Pharmacokinetic (PK) assessments for PF-07994525
Measured: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Single, Multiple Dose and food effect: Time to Maximum concentration (Tmax)
Pharmacokinetic (PK) assessments for PF-07994525
Measured: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Single, Multiple Dose and food effect: AUC from time zero to time of last measurable concentration (AUClast)
Pharmacokinetic (PK) assessments for PF-07994525
Measured: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Single Dose and food effect: Terminal Elimination half-life (t1/2) as data permit
Pharmacokinetic (PK) assessments for PF-07994525
Measured: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Single Dose and food effect: AUC versus time curve from time 0 extrapolated to infinity (AUCinf) as data permit
Pharmacokinetic (PK) assessments for PF-07994525
Measured: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Single, Multiple Dose and food effect: apparent clearance of drug (CL/F) as data permit
Pharmacokinetic (PK) assessments for PF-07994525
Measured: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Single, Multiple Dose and food effect: Apparent volume of distribution during terminal phase (Vz/F) as data permit
Pharmacokinetic (PK) assessments for PF-07994525
Measured: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Multiple Dose: AUC at steady state over the dosing interval (AUCtau) as data permit
Pharmacokinetic (PK) assessments for PF-07994525
Measured: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Multiple Dose: Cmin as data permit
Pharmacokinetic (PK) assessments for PF-07994525
Measured: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Multiple Dose: Accumulation ratio (Rac) as data permit
Pharmacokinetic (PK) assessments for PF-07994525
Measured: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
AUC from time zero to time of last measurable concentration (AUClast)
PK parameters of CYP3A4 probe substrate midazolam with and without PF-07994525
Measured: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Time to Maximum concentration (Tmax)
PK parameters of CYP3A4 probe substrate midazolam with and without PF-07994525
Measured: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Maximum Observed Concentration (Cmax)
PK parameters of CYP3A4 probe substrate midazolam with and without PF-07994525
Measured: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Feb 2026
- Study start1 Jul 2026
- Primary completion10 Jul 2029 (estimated)
- Study completion10 Jul 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Advanced MalignanciesStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Sequential
- Masking
- None (open label)
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07426757
- Sponsor's protocol ID
- C6331001
- Other IDs
- KAT2i
- Status last verified
- Nov 2026
- First submitted
- 16 Feb 2026
- Last updated
- 5 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
Study at a glance
From the registry record, last updated by the sponsor on 5 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- AN OPEN-LABEL PHASE 1 STUDY TO EVALUATE PF-07994525 IN PARTICIPANTS WITH ADVANCED MALIGNANCIES
- ClinicalTrials.gov ID
- NCT07426757
- Acronym / sponsor ID
- C6331001
- Conditions
- Advanced Malignancies, Advanced Cancer
- Keywords
- Advanced Malignancies, Advanced Cancers, Advanced Cancer
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- 1 Jul 2026 (actual)
- Primary completion
- 10 Jul 2029 (estimated)
- Study completion
- 10 Jul 2030 (estimated)
- First posted
- 23 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is an open-label, dose escalation and dose expansion study evaluating the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and antitumor activity of PF-07994525 in participants with R/R MM.
The study will consist of 2 parts: Part 1 (Dose Escalation) will consist of PF-07994525 dose escalation to assess the safety, tolerability, and preliminary antitumor activity in participants with R/R MM. In Part 2 (Dose expansion), PF-07994525 may be evaluated in additional participants with R/R MM to further assess safety, PK, PD, and preliminary anti-tumor activity.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Part 1 | Experimental | Drug: PF-07994525, Drug: MidazolamMonotherapy Dose Expansion |
| Part 2 | Experimental | Drug: PF-07994525Monotherapy Dose Escalation |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Participants aged 18 years or older (or the minimum age of consent in accordance with local regulations) at the time of informed consent.
- Prior diagnosis of MM as defined according to IMWG criteria (Rajkumar et al. 2014)
- Serum M-protein >0.5 g/dL by serum protein electrophoresis (SPEP)
- Urinary M-protein excretion >200 mg/24 hours by urine protein electrophoresis (UPEP)
- Serum immunoglobulin Free Light Chain (FLC) ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio (<0.26 or >1.65)
Key exclusion criteria (4 listed)
- Active plasma cell leukemia, Smoldering MM, Waldenströms macroglobulinemia, Amyloidosis, POEMS Syndrome.
- Autologous stem cell transplant within 12 weeks prior to enrollment or active Graft-versus-host disease (GVHD).
- Active or suspected cerebral/meningeal disease related to the underlying malignancy.
- Any active, uncontrolled bacterial, fungal, or viral infection, including (but not limited to) COVID-19, Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), known HIV or AIDS related illness, unless deemed not clinically significant by the investigator (eg, onychomycosis).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PF-07994525Oral administration | Drug | Part 1, Part 2 |
| MidazolamOral administration | Drug | Part 1 |
Primary outcome
Type, incidence and severity of participants with adverse events (AEs)
Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Type, incidence, severity (graded by National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] version 5.0), timing, seriousness, and relatedness of adverse events (AEs)
Type, incidence and severity of participants with laboratory abnormalities
Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Type, incidence, and severity (graded by NCI CTCAE version 5.0) of laboratory abnormalities
Number of participants with dose modifications
Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Frequency of dose modifications (eg, dose delay, treatment interruptions, dose reductions, and treatment discontinuations) due to AEs
Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)
Time frame: Baseline to end of DLT evaluation period
Occurrence of DLTs as defined by the protocol
Part 1: Recommended Monotherapy Dose for Expansion (RDE)
Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
RDE will be based on cumulative safety, preliminary antitumor activity and pharmacokinetics findings
Part 2: Recommended Dose for future development
Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Safety, and preliminary anti-tumor activity
20 secondary outcomes
Objective response rate (ORR) per International Myeloma Working Group (IMWG) response criteria as determined by investigator.
Time frame: Baseline until the date of the first documentation of disease progression, death, or start of new anticancer therapy (approximately 2 years)
Complete response rate (CRR) per International Myeloma Working Group (IMWG) response criteria as determined by investigator.
Time frame: Baseline until the date of the first documentation of disease progression, death, or start of new anticancer therapy (approximately 2 years)
Time to response (TTR) per IMWG as determined by investigator
Time frame: Baseline until the date of the first documentation of disease progression, death, or start of new anticancer therapy (approximately 2 years)
Duration of response (DOR) per IMWG as determined by investigator
Time frame: Baseline until the date of the first documentation of disease progression, death, or start of new anticancer therapy (approximately 2 years)
Duration of complete response (DOCR) per IMWG as determined by investigator
Time frame: Baseline until the date of the first documentation of disease progression, death, or start of new anticancer therapy (approximately 2 years)
Progression-free survival (PFS) per IMWG as determined by investigator
Time frame: Baseline until the date of the first documentation of disease progression, death, or start of new anticancer therapy (approximately 2 years)
Overall survival (OS)
Time frame: Baseline until the date of the first documentation of disease progression, death, or start of new anticancer therapy (approximately 2 years)
Single, Multiple Dose and food effect: Maximum Observed Concentration (Cmax)
Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Single, Multiple Dose and food effect: Time to Maximum concentration (Tmax)
Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Single, Multiple Dose and food effect: AUC from time zero to time of last measurable concentration (AUClast)
Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Single Dose and food effect: Terminal Elimination half-life (t1/2) as data permit
Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Single Dose and food effect: AUC versus time curve from time 0 extrapolated to infinity (AUCinf) as data permit
Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Single, Multiple Dose and food effect: apparent clearance of drug (CL/F) as data permit
Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Single, Multiple Dose and food effect: Apparent volume of distribution during terminal phase (Vz/F) as data permit
Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Multiple Dose: AUC at steady state over the dosing interval (AUCtau) as data permit
Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Multiple Dose: Cmin as data permit
Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Multiple Dose: Accumulation ratio (Rac) as data permit
Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
AUC from time zero to time of last measurable concentration (AUClast)
Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Time to Maximum concentration (Tmax)
Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Maximum Observed Concentration (Cmax)
Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Nov 2026.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
- Individual participant dataSharing planned: No. Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Related trials for Advanced Malignancies
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
Active, not recruitingPhase 3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Carcinoma, Renal Cell
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 1
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor
Neoplasms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Pfizer CT.gov Call Center study director
Pfizer
30 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing PF-07994525 and Midazolam in people with Advanced Malignancies and Advanced Cancer, run by Pfizer at 30 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 30 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Pfizer CT.gov Call Center (1-800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Type, incidence and severity of participants with adverse events (AEs) (time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Nov 2026.